Compare Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) vs Quantumscape Corp (QS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Maravai LifeSciences Holdings Inc. Class A Common Stock vs Quantumscape Corp — how do they compare? Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M), while Quantumscape Corp trades at $3.91 (market cap $2.55B). The key difference: Quantumscape Corp is far larger — about 2.6× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Maravai LifeSciences Holdings Inc. Class A Common Stock is trading nearer its 52-week high, Quantumscape Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days and Quantumscape Corp for 37 Days on average.
| MRVI | QS | |
|---|---|---|
Market Cap | $972.90M | $2.55B |
Volume | 4,325,710 | 12,145,789 |
Sector | Health | Consumer Cyclical |
52-Week High | $9.00 | $18.44 |
52-Week Low | $2.83 | $3.93 |
Typical Hold Time | 0 Days | 37 Days |
Enterprise Value | $1.08B | $1.76B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
QuantumScape (QS) trades at $3.93, down 7.96% today, reflecting ongoing investor skepticism about its path to commercialization. The company remains pre-revenue with significant losses (-$435.05M net income in 2025) and negative profitability metrics (ROE -39.08%). Technical indicators show a bearish trend with oversold RSI readings, while analyst consensus leans heavily toward Hold (72.73%) with a $10.35 price target suggesting potential upside if execution improves.
QS faces substantial execution risk with commercialization delayed until at least 2029 and intense competition in solid-state batteries. The stock offers high-risk speculative potential for investors betting on breakthrough technology adoption, but requires patience through years of cash burn and dependency on future manufacturing success with partners like Volkswagen.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →About Quantumscape Corp
QuantumScape Corp is engaged in the development of next-generation solid-state lithium-metal batteries for use in electric vehicles. It developed anode-less cell design, which delivers high energy density while lowering material costs and simplifying manufacturing.
Read more on QS →
